HIV

The burden of childhood illness does not end at hospital discharge. Many children living with HIV, especially in low-resource settings, remain at risk of severe complications and even death in the weeks following discharge.

Hi all, I am Kehlani, one of the Penta Young Reporters.

This article is about how HIV and stigma can affect the mental health of young people and how social norms and gendered attitudes in the UK significantly impact the Sexual Reproductive Health (SRH) outcomes for boys and girls in the UK. 

A significant milestone has been reached in the fight against paediatric HIV with the enrolment of the first participants in the UNIVERSAL1 trial. This achievement is a testament to the tremendous effort and dedication of the site staff in Uganda and Zimbabwe. 

It was in my early days as a Penta Young Reporter that I was given the opportunity to interview the highly regarded Paediatric HIV consultant, Dr. Noella Pereira from the Penta ID Network.

Laurus Labs has submitted an application to the US Food and Drug Administration (FDA) for the tentative approval of paediatric Darunavir/ritonavir (pDRV/r (120/20 mg)). UNIVERSAL is the first product development project from the World Health Organisation’s (WHO) GAP-F project which was established to promote the development of safer,

Arriving at the International Workshop on Pediatrics & HIV 2024, we felt a mix of nerves and excitement, knowing we were about to be surrounded by experts who spend their careers understanding and fighting the virus we live with every day.

A new collaborative project called SUPPORT has officially launched to train the next generation of researchers who will focus on preventing mortality among these children.

The SUPPORT initiative,

A new collaborative initiative, SUPPORT – Supporting the next generation of African experts on preventing mortality among children living with HIV through translational training, has officially launched.

From 14 to 16 May, 2024, PentaTr@ining in collaboration with UNICEF, the World Health Organization (WHO) and with support from the International Organization for Migration (IOM),

EPIICAL’s EARTH Study reveals challenges persist for infants in Africa with HIV despite early treatment

The EARTH study findings published in eClinical Medicine shed light on the ongoing struggle for infants with HIV in Africa.

The CARMA Global study, part of the EPIICAL project, has successfully met its recruitment target and recruited 99 children and adolescents living with HIV from across the globe.

In recent years, advancements in medical research have paved the way for an array of treatment options for children living with HIV. The efforts of scientists and researchers globally, have led to continuous refinement and improvement of existing regimens.

In the quest to enhance our understanding of paediatric HIV and improve treatment outcomes, the EPIICAL project has worked tirelessly for the past eight years to gather and generate knowledge on HIV in children.

The D3 trial is excited to announce that it has successfully completed recruitment in the trial at an exceptional speed. D3 is looking to see if a new tablet, a combination of two anti-HIV medicines,

FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (Nasdaq: GILD) is pleased to announce two public-private partnerships. The first will accelerate the development of an investigational dispersible pediatric formulation containing emtricitabine and tenofovir alafenamide (F/TAF).

Between the months of April and May 2023, Penta hosted advisory group meetings where young people between the ages of 15 and 19 from South Africa, Argentina, the United Kingdom and Thailand,

Findings from the Strategy for Maintenance of HIV suppression with integrase inhibitor + darunavir/ritonavir in children (PENTA-17) trial, simply known as SMILE, were published in eClinicalMedicine on 2 June 2023.

The inaugural Clinical Trial Management training program took place online on Wednesday, 14 June 2023, after 428 participants registered. The session was well attended by up to 168 clinical trial staff representing 30 countries.